Pirfenidone photosensitization in patients with idiopathic pulmonary fibrosis a case series

C Droitcourt 1, 2, 3 Henri Adamski 1, * A Polat 1 E Polard 1 M Kerjouan 1 B Arnouat 1 M Le Garrec 1 E Oger 3, 1 A Dupuy 1, 3 S Jouneau 1, 4
* Corresponding author
1 CHU Pontchaillou [Rennes]
2 CIC - Centre d'Investigation Clinique [Rennes]
3 REPERES - Recherche en Pharmaco-épidémiologie et Recours aux Soins
4 Irset - Institut de recherche en santé, environnement et travail
Abstract : The oral antifibrotic agent, pirfenidone (PFD), 5-methyl-l-phenyl-[1H]-pyridine, is used to treat idiopathic pulmonary fibrosis (IPF), a chronic and fatal lung disease. In trials, PFD reduces disease progression and decreases mortality. The most common adverse events of PFD are skin manifestations (25%), described as photosensitivity or rash, but they are not well characterized. The objective of the present real-life study was to address the question of skin manifestations in patients treated with PFD for IPF.
Document type :
Journal articles
Complete list of metadatas
https://hal-univ-rennes1.archives-ouvertes.fr/hal-01771415
Contributor : Laurent Jonchère <>
Submitted on : Thursday, April 26, 2018 - 1:43:16 PM
Last modification on : Friday, November 29, 2019 - 1:45:38 AM
Long-term archiving on: Tuesday, September 25, 2018 - 1:46:59 PM

File

Pirfenidone photosensitization...
Files produced by the author(s)

Identifiers

Collections

UNIV-RENNES1 | IRSET | UR1-UFR-SVE | IRSET-1 | CIC203 | REPERES | IRSET-EHESP | EHESP | UNIV-ANGERS | UNIV-RENNES | USPC | BIOSIT | CIC | IRSET-HIAEC

Citation

C Droitcourt, Henri Adamski, A Polat, E Polard, M Kerjouan, et al.. Pirfenidone photosensitization in patients with idiopathic pulmonary fibrosis a case series. British Journal of Dermatology, Wiley, 2018, 178 (3), pp.e222-e223. ⟨10.1111/bjd.16016⟩. ⟨hal-01771415⟩

Export

BibTeX TEI DC DCterms EndNote

Share

Metrics

Record views

279

Files downloads

205